一种基于血浆MIG、NGF和GZMB组合评估HIV感染者免疫重建不全风险的方法及试剂盒
By combining multiple biomarker detection methods of MIG, NGF, and GZMB with multiplex magnetic bead detection and enzyme-linked immunosorbent assay (ELISA), the problem of difficulty in assessing the risk of incomplete immune reconstitution in HIV-infected individuals in existing technologies has been solved, achieving efficient and stable risk assessment and early intervention.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV
- Filing Date
- 2026-04-01
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies struggle to systematically integrate inflammation, chemokines, and extracellular matrix factors, lacking small, multi-marker combinations to assess the risk of incomplete immune reconstitution in HIV-infected individuals. Existing indicators have limited ability to stratify IR and INR, making it difficult to identify high-risk individuals early in the ART process.
A multi-marker combination detection method based on plasma chemokine MIG, nerve growth factor NGF and granzyme B (GZMB) was adopted, combined with multiplex magnetic bead detection and enzyme-linked immunosorbent assay (ELISA), to construct a risk assessment model, optimize classification performance through machine learning algorithms, and provide a small multi-marker combination detection kit.
It enables effective assessment of the risk of incomplete immune reconstitution in HIV-infected individuals, improves the sensitivity, specificity, and stability of prediction, provides a basis for early clinical intervention and individualized management, and reduces testing costs and operational complexity.
Smart Images
Figure CN121964156B_ABST